Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Corcept Therapeutics (CORT.O), opens new tab said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial.

Mid-cap stocks surged in the past week, including CORT, COOP, and CRWV. GOOG may rent AI servers from CRWV. PRGS and LOAR ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...